tirzepatide risk linked to lower for death, adverse CV and kidney outcomes vs. GLP-1s Study flags need to monitor

Keep a dose log

It leads to various health conditions, such as type 2 diabetes mellitus, cardiovascular disease, hypertension, dyslipidaemia, and non-alcoholic fatty liver disease

Future research should prioritize the development of next-generation agonists, explore combination therapies, and integrate precision medicine approaches to optimize patient outcomes

Large observational studies have also linked GLP-1 receptor agonists with lower rates of alcohol, nicotine, cannabis, cocaine, and opioid-related disorders, along with reduced SUD-related hospitalizations and mortality

Always confirm timing with your prescriber

53 Future Directions and Unanswered Questions Despite recent evidence from clinical trials, key questions remain about the optimal use of GLP-1RAs for HF